This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Krasinski, K. Articles by Losordo, D. W. Search for Related Content PubMed PubMed Citation Articles by Krasinski, K. Articles by Losordo, D. W. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Angioplasty Carotid Artery Disease Hazardous Substances DB NITRIC OXIDE Related Collections Restenosis Restenosis Growth factors/cytokines Endothelium/vascular type/nitric oxide

(Circulation. 2001;104:1754.)
© 2001 American Heart Association, Inc.

Brief Rapid Communications

In Vivo Blockade of Tumor Necrosis Factor- Accelerates Functional Endothelial Recovery After Balloon Angioplasty

Kevin Krasinski, BA; Ioakim Spyridopoulos, MD; Marianne Kearney, BS; Douglas W. Losordo, MD

From the Division of Cardiovascular Medicine, St. Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, Mass.

Correspondence to Douglas W. Losordo, MD, St. Elizabeth’s Medical Center, 736 Cambridge Street, Boston, MA 02135.

Background— Tumor necrosis factor- (TNF) is expressed locally in arteries at sites of balloon injury. In vitro studies have shown that TNF inhibits cell cycle progression and induces apoptosis in endothelial cells. Accordingly, we performed a series of experiments to test the hypothesis that inhibiting TNF could accelerate endothelial recovery after angioplasty.

Methods and Results— TNF soluble receptor (TNFsr) has been shown to neutralize the actions of TNF in vitro and in vivo. Sprague-Dawley rats received TNFsr versus control IgG through an intraperitoneal injection. De-endothelializing balloon injury was then performed, and animals were killed after 1 week to evaluate re-endothelialization (Evans blue dye staining) and after 2 weeks to evaluate re-endothelialization and endothelial function. At both time points, blockade of TNF using TNFsr resulted in an increase in re-endothelialization, as measured as absolute area and percent area re-endothelialized. TNFsr also accelerated functional endothelial recovery, which manifest as an increase in nitric oxide production. Neointimal thickening was also shown inhibited.

Conclusions— In vivo blockade of TNF accelerates functional endothelial recovery after barotraumatic de-endothelializing injury. These findings suggest that locally expressed TNF acts to inhibit functional endothelial recovery after angioplasty and that transient blockade of TNF may improve the long-term success of angioplasty.

Key Words: endothelium • angioplasty • restenosis • tumor necrosis factor

This article has been cited by other articles:

				J. Rajasingh, E. Bord, C. Luedemann, J. Asai, H. Hamada, T. Thorne, G. Qin, D. Goukassian, Y. Zhu, D. W. Losordo, et al. IL-10-induced TNF-alpha mRNA destabilization is mediated via IL-10 suppression of p38 MAP kinase activation and inhibition of HuR expression FASEB J, October 1, 2006; 20(12): 2112 - 2114. [Abstract] [Full Text] [PDF]

				S. Grundmann, I. Hoefer, S. Ulusans, N. van Royen, S. H. Schirmer, C. K. Ozaki, C. Bode, J. J. Piek, and I. Buschmann Anti-tumor necrosis factor-{alpha} therapies attenuate adaptive arteriogenesis in the rabbit Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1497 - H1505. [Abstract] [Full Text] [PDF]

				D. Gurantz, A. Yndestad, B. Halvorsen, O. V. Lunde, J. H. Omens, T. Ueland, P. Aukrust, C. D. Moore, J. Kjekshus, and B. H. Greenberg Etanercept or intravenous immunoglobulin attenuates expression of genes involved in post-myocardial infarction remodeling Cardiovasc Res, July 1, 2005; 67(1): 106 - 115. [Abstract] [Full Text] [PDF]

				E. W. Raines and N. Ferri Thematic Review Series: The Immune System and Atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease J. Lipid Res., June 1, 2005; 46(6): 1081 - 1092. [Abstract] [Full Text] [PDF]

				B. P. Helmke Molecular Control of Cytoskeletal Mechanics by Hemodynamic Forces Physiology, February 1, 2005; 20(1): 43 - 53. [Abstract] [Full Text] [PDF]

				L. Zhang, K. Peppel, L. Brian, L. Chien, and N. J. Freedman Vein Graft Neointimal Hyperplasia Is Exacerbated by Tumor Necrosis Factor Receptor-1 Signaling in Graft-Intrinsic Cells Arterioscler Thromb Vasc Biol, December 1, 2004; 24(12): 2277 - 2283. [Abstract] [Full Text] [PDF]

				K. V. RAMANA, A. BHATNAGAR, and S. K. SRIVASTAVA Inhibition of aldose reductase attenuates TNF-{alpha}-induced expression of adhesion molecules in endothelial cells FASEB J, August 1, 2004; 18(11): 1209 - 1218. [Abstract] [Full Text] [PDF]

				D. H. Walter, M. Cejna, L. Diaz-Sandoval, S. Willis, L. Kirkwood, P. W. Stratford, A. B. Tietz, R. Kirchmair, M. Silver, C. Curry, et al. Local Gene Transfer of phVEGF-2 Plasmid by Gene-Eluting Stents: An Alternative Strategy for Inhibition of Restenosis Circulation, July 6, 2004; 110(1): 36 - 45. [Abstract] [Full Text] [PDF]

				H. D. I. Anderson, D. Rahmutula, and D. G. Gardner Tumor Necrosis Factor-{alpha} Inhibits Endothelial Nitric-oxide Synthase Gene Promoter Activity in Bovine Aortic Endothelial Cells J. Biol. Chem., January 9, 2004; 279(2): 963 - 969. [Abstract] [Full Text] [PDF]

				R. Kishore, C. Luedemann, E. Bord, D. Goukassian, and D. W. Losordo Tumor Necrosis Factor-Mediated E2F1 Suppression in Endothelial Cells: Differential Requirement of c-Jun N-Terminal Kinase and p38 Mitogen-Activated Protein Kinase Signal Transduction Pathways Circ. Res., November 14, 2003; 93(10): 932 - 940. [Abstract] [Full Text] [PDF]

				D. A. Goukassian, R. Kishore, K. Krasinski, C. Dolan, C. Luedemann, Y.-s. Yoon, M. Kearney, A. Hanley, H. Ma, T. Asahara, et al. Engineering the Response to Vascular Injury: Divergent Effects of Deregulated E2F1 Expression on Vascular Smooth Muscle Cells and Endothelial Cells Result in Endothelial Recovery and Inhibition of Neointimal Growth Circ. Res., July 25, 2003; 93(2): 162 - 169. [Abstract] [Full Text] [PDF]

				J. H. Von der Thusen, J. Kuiper, T. J. C. Van Berkel, and E. A. L. Biessen Interleukins in Atherosclerosis: Molecular Pathways and Therapeutic Potential Pharmacol. Rev., March 1, 2003; 55(1): 133 - 166. [Abstract] [Full Text] [PDF]

				M. Chen, C. Capps, J. T. Willerson, and P. Zoldhelyi E2F-1 Regulates Nuclear Factor-{kappa}B Activity and Cell Adhesion: Potential Antiinflammatory Activity of the Transcription Factor E2F-1 Circulation, November 19, 2002; 106(21): 2707 - 2713. [Abstract] [Full Text] [PDF]

				R. Kishore, I. Spyridopoulos, C. Luedemann, and D. W. Losordo Functionally Novel Tumor Necrosis Factor-{alpha}-Modulated CHR-Binding Protein Mediates Cyclin A Transcriptional Repression in Vascular Endothelial Cells Circ. Res., August 23, 2002; 91(4): 307 - 314. [Abstract] [Full Text] [PDF]

				I. E. Hoefer, N. van Royen, J. E. Rectenwald, E. J. Bray, Z. Abouhamze, L. L. Moldawer, M. Voskuil, J. J. Piek, I. R. Buschmann, and C. K. Ozaki Direct Evidence for Tumor Necrosis Factor-{alpha} Signaling in Arteriogenesis Circulation, April 9, 2002; 105(14): 1639 - 1641. [Abstract] [Full Text] [PDF]